Mads Krogsgaard Thomsen, Chief Executive Officer, Novo Nordisk Foundation

In March 2021, Mads Krogsgaard Thomsen was appointed as CEO of the Novo Nordisk Foundation, one of the world’s largest foundations that supports scientific, humanitarian and social purposes to improve the lives of people and the sustainability of society.

Between 1991-2021, Mads Krogsgaard Thomsen held various positions at the pharmaceutical company Novo Nordisk, most recently as Chief Scientific Officer and Executive Vice President of Research & Development. He is currently a member of the board of BB Biotech AG.

Mads Krogsgaard Thomsen holds a DVM, a PhD and a DSc from the Faculty of Health and Medical Sciences at the University of Copenhagen, where he also serves as Adjunct Professor of Pharmacology.

Website: www.novonordiskfonden.dk/en/

Kasim Kutay, Chief Executive Officer, Novo Holdings A/S

Kasim Kutay has served as CEO of Novo Holdings A/S since joining the company in 2016. Headquartered in Denmark and with offices in San Francisco, Boston, Singapore and London, Novo Holdings A/S is a world-leading life sciences investor.

Prior to joining Novo Holdings A/S, Kasim Kutay served as managing director, co-head of Europe and member of the Global Management Committee of Moelis & Co. in the UK (2009-2016).

From 1989 to 2007, Kasim Kutay held several positions at Morgan Stanley, UK, including as chair of the European Healthcare Group.

Kasim Kutay holds a BSc in Economics and a MSc in Politics of the World Economy from the London School of Economics and Political Science.

Website: www.novoholdings.dk